Reprise Biomedical, Inc. is excited to announce a significant funding milestone that will further propel its mission to revolutionize healing with advanced biological medical devices. The company successfully raised $6,300,000 in its latest funding round, marking an important step in solidifying its commitment to innovation and improving patient outcomes. Founded in July 2019 as a spin-off from Miromatrix Medical Inc., Reprise Biomedical has quickly made an impact in the medical industry by taking ownership of the manufacturing, marketing, and distribution of two notable products: MiroDerm biologic wound matrix and MiroFlex biologic matrix for soft tissue reinforcement. With this new capital infusion, the company will accelerate research, development, and commercialization efforts to expand its suite of cutting-edge solutions.
At the heart of Reprise鈥檚 progress is its proprietary perfusion decellularization technology, a platform that is paving the way for groundbreaking products addressing unmet surgical needs. The latest addition to their portfolio, the Miro3D wound matrix, exemplifies the company鈥檚 innovative spirit by offering a unique three-dimensional solution specifically designed for deep and tunneling wounds. This advancement not only broadens their wound management offerings but also demonstrates a commitment to providing superior healing options for patients who require specialized care.
The substantial funding will empower Reprise Biomedical to refine its existing product lines and fuel the development of next-generation medical devices. As the company continues to drive forward its vision of more effective and comprehensive healing solutions, this investment underlines the confidence of stakeholders in Reprise鈥檚 ability to transform the future of surgical care and improve the lives of patients worldwide.
